Article Data

  • Views 208
  • Dowloads 108

Case Reports

Open Access

Complete remission of recurrent and refractory ovarian cancers using weekly administration of bevacizumab and gemcitabine/oxaliplatin: report of two cases

  • M. Takano1,2,*,
  • Y. Ikeda2,3
  • K. Kudoh2,4
  • T. Kita2,5
  • N. Sasaki1,2
  • Y. Kikuchi2

1Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Saitama

2Department of Gynecology, Ohki Memorial Kikuchi Cancer Clinic for Women, Tokorozawa, Saitama

3Department of Obstetrics and Gynecology, Tokyo University School of Medicine, Bunkyo-ku, Tokyo

4Department of Obstetrics and Gynecology, National Hospital Organization Nishi-Saitama Chuo Hospital, Tokorozawa, Saitama

5Department of Obstetrics and Gynecology, Nara Prefectural, Nara Hospital, Nara (Japan).

DOI: 10.12892/ejgo340118 Vol.34,Issue 1,January 2013 pp.90-93

Published: 10 January 2013

*Corresponding Author(s): M. Takano E-mail:


Background: A combination therapy with gemcitabine and oxaliplatin (GEMOX) yielded a moderate activity in platinum-resistant ovarian cancers; however, frequent severe toxicities, such as thrombocytopenia and neurotoxicity, were observed. A certain modification of schedule might therefore facilitate the clinical application of the regimen. The authors report two cases that achieved complete response to a weekly administration of bevacizumab and GEMOX. Materials and Methods: Two patients with platinum-resistant recurrent ovarian cancers received a weekly regimen of GEMOX with bevacizumab: 2 mg/kg of bevacizumab, 300 mg/m2 of gemcitabine, and 30 mg/m2 of oxaliplatin, three weeks on and one week off, Q4 weeks. Complete remission was observed after three to four courses of therapy. Hematologic and non-hematologic toxicities more than grade 2 were not observed during chemotherapy. The patients are now without tumor progression more than 12 months after initiation of therapy. Conclusion: Weekly administration of bevacizumab and GEMOX had potential activity in recurrent and refractory ovarian carcinomas. These findings warrant necessity of further trial in such clinical settings.


Ovarian cancer; Recurrence; Weekly therapy; Bevacizumab; Gemcitabine/oxaliplatin.

Cite and Share

M. Takano,Y. Ikeda,K. Kudoh,T. Kita,N. Sasaki,Y. Kikuchi. Complete remission of recurrent and refractory ovarian cancers using weekly administration of bevacizumab and gemcitabine/oxaliplatin: report of two cases. European Journal of Gynaecological Oncology. 2013. 34(1);90-93.


[1] McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y. et al.: “Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with Stage III and Stage IV ovarian cancer”. N. Engl. J. Med., 1996, 334, 1.

[2] Mutch D.G., Orlando M., Goss T., Teneriello M.G., Gordon A.N., McMeekin S.D. et al.: “Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer”. J. Clin. Oncol., 2007, 25, 2811.

[3] Ferrandina G., Ludovisi M., Lorusso D., Pignata S., Breda E., Savarese A. et al.: “Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer”. J. Clin. Oncol. 2008, 26, 890.

[4] Ray-Coquard I., Weber B., Cretin J., Haddad-Guichard Z., Lévy E., Hardy-Bessard A.C. et al. GINECO group: “Gemcitabineoxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group”. Br. J. Cancer, 2009, 100, 601.

[5] Horowitz N.S., Penson R.T., Duda D.G., di Tomaso E., Boucher Y., Ancukiewicz M. et al.: “Safety, efficacy, and biomarker exploration in a phase II study of bevacizumab, oxaliplatin, and gemcitabine in recurrent müllerian carcinoma”. Clin. Ovarian Cancer Other Gynecol. Malig., 2011, 4, 26.

[6] Raspagliesi F., Zanaboni F., Vecchione F., Hanozet F., Scollo P., Ditto A. et al.: “Gemcitabine combined with oxaliplatin (GEMOX) as second-line chemotherapy in patients with advanced ovarian cancer refractory or resistant to platinum and taxane”. Oncology, 2004, 67, 376.

[7] Harnett P., Buck M., Beale P., Goldrick A., Allan S., Fitzharris B. et al.: “Phase II study of gemcitabine and oxaliplatin in patients with recurrent ovarian cancer: an Australian and New Zealand Gynaecological Oncology Group study”. Int. J. Gynecol. Cancer, 2007, 17, 359.

[8] Germano D., Rosati G., Manzione L.: “Gemcitabine combined with oxaliplatin (GEMOX) as salvage treatment in elderly patients with advanced ovarian cancer refractory or resistant to platinum: a single institution experience”. J. Chemother., 2007, 19, 577.

[9] Kalykaki A., Papakotoulas P., Tsousis S., Boukovinas I., Kalbakis K., Vamvakas L. et al. Hellenic Oncology Research Group: “Gemcitabine plus oxaliplatin (GEMOX) in pretreated patients with advanced ovarian cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG)”. Anticancer Res., 2008, 28, 495.

[10] Klement G., Huang P., Mayer B., Green S.K., Man S., Bohlen P. et al.: “Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrugresistant human breast cancer xenografts”. Clin. Cancer Res., 2002, 8, 221.

[11] Giuntoli R.L. 2nd, Webb T.J., Zoso A., Rogers O., Diaz-Montes T.P., Bristow R.E., Oelke M.: “Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity”. Anticancer Res., 2009, 29, 2875.

[12] Kobold S., Hegewisch-Becker S., Oechsle K., Jordan K., Bokemeyer C., Atanackovic D.: “Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites?”. Oncologist, 2009, 14, 1242.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time